Photo from wikipedia
Palbociclib is an oral, small-molecule, specific, and reversible inhibitor of cyclin-dependent kinases 4 and 6, recently approved for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative, metastatic… Click to show full abstract
Palbociclib is an oral, small-molecule, specific, and reversible inhibitor of cyclin-dependent kinases 4 and 6, recently approved for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2–negative, metastatic breast cancer. Registration trials witnessed a few treatment-emergent liver safety issues, with one liver-related death that was not considered to be related to palbociclib. In this postmarketing report, we characterize two patients with hepatic failure and liver-related death following treatment with palbociclib.
Journal Title: Hepatology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!